Global Pharma Giant BeOne Opens Israeli Branch as Biotech Sector Expands
International pharmaceutical giant BeOne establishes an Israeli branch. Meanwhile, a new study links nighttime eating to liver disease, and biotech firm Nano24 reports clinical trial success.
A $45 billion pharmaceutical giant is expanding its footprint to Israel as global biotech trends shift. BeOne, formerly known as BeiGene, an innovative international pharmaceutical company originating in China and traded on Nasdaq with a valuation of $45 billion, is establishing a direct local branch in Israel for product marketing. The Israeli operation will be headed by Roy Eliya, who until recently led Market Access Israel at American pharmaceutical giant MSD.
Origins and Global Expansion
Founded in 2010, BeiGene was a pioneer of the biotech innovation wave in China and one of the first Chinese companies to secure FDA approval in 2019. It was established by John Oyler, an American resident in China, and Dr. Xiaodong Wang, who studied in the United States and returned to his homeland with a vision to develop local biotech and bring scientists back to the country. Amid geopolitical tensions, the company's status remains unique. In recent years, it has undergone an internationalization process, downplaying its Chinese origins: shifting its headquarters to Switzerland, securing a 17% stake by American biotech giant Amgen, and building extensive R&D and manufacturing operations in the United States. Last August, the company announced an additional $300 million investment in U.S. manufacturing to circumvent American market tariffs.
Clinical Trials and Market Performance
The company currently markets three oncology and hematology drugs. During an investor earnings call last August, management revealed that five additional cancer therapies are slated to enter advanced clinical trials over the next 18 months. Over the past six months, the company's stock has risen by approximately 7%.
Nighttime Eating and Liver Disease Risk
Eating late at night is associated with a 20% to 30% higher risk of liver disease, according to a study published by researchers from Oregon Health & Science University (OHSU) in the journal Clinical Gastroenterology and Hepatology. The researchers analyzed data from 200,000 representative individuals and found that late eaters exhibited a higher likelihood of non-alcoholic fatty liver disease (NAFLD) and liver scarring. The team applied statistical processing to control for age, weight, total daily caloric intake, smoking, physical activity, alcohol consumption, and shift work, noting that the association persisted even after neutralizing these variables.
National Clinical Research Initiative
The Ministry of Health announced that the government has approved a national program to strengthen clinical research and trials activity in Israel. The decision includes a mechanism for mutual recognition among medical institutions, such as hospitals and health maintenance organizations, regarding Helsinki committees that oversee trial ethics. Furthermore, certain approval authorities will be transferred from the Ministry of Health directly to trial conductors, alongside the integration of digital tools for managing applications and reporting results.
Breakthrough in Israeli Biotech Trial
Israeli biotech firm Nano24 announced successful results in a Phase IIb clinical trial evaluating inhaled exosomes for patients suffering from Acute Respiratory Distress Syndrome (ARDS), which can stem from pneumonia, gastric aspiration, or sepsis. Exosomes are tiny cell-like vesicles produced internally by cells, carrying genetic cargo, proteins, and metabolites that facilitate intercellular communication. In Nano24's trial, 85% of patients treated with the proprietary exosomes were free from respiratory failure by the seventh day of treatment, compared to just 33% in the control group.
